Vaccines for prevention of meningococcal disease.
作者信息
Frasch C E
机构信息
Divison of Bacterial Products, Center for Biologics Evaluation and Research, Bethesda, Maryland 20892.
出版信息
Clin Microbiol Rev. 1989 Apr;2 Suppl(Suppl):S134-8. doi: 10.1128/CMR.2.Suppl.S134.
Abstract
摘要
相似文献
1
Vaccines for prevention of meningococcal disease.预防脑膜炎球菌病的疫苗。
Clin Microbiol Rev. 1989 Apr;2 Suppl(Suppl):S134-8. doi: 10.1128/CMR.2.Suppl.S134.
2
Status of a group B Neisseria meningitidis vaccine.B 群脑膜炎奈瑟菌疫苗的现状
Eur J Clin Microbiol. 1985 Dec;4(6):533-6. doi: 10.1007/BF02013388.
3
Neisseria meningitidis: vaccines and vaccine candidates.脑膜炎奈瑟菌：疫苗及候选疫苗
J Infect. 1996 Nov;33(3):153-7. doi: 10.1016/s0163-4453(96)92081-2.
4
[Vaccines against Neisseria meningitidis].[抗脑膜炎奈瑟菌疫苗]
Enferm Infecc Microbiol Clin. 1992 May;10(5):296-301.
5
Meningococcal meningitis.
Lancet. 1989 Mar 25;1(8639):647-8.
6
The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.B群脑膜炎奈瑟菌的荚膜多糖作为疫苗开发的载体。
Contrib Microbiol Immunol. 1989;10:151-65.
7
Vaccines against meningococcal meningitis: current status.抗脑膜炎球菌性脑膜炎疫苗：现状
Epidemiol Bull. 1994 Jul;15(2):13-5.
8
Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.巴西里约热内卢B群脑膜炎球菌疫苗直接有效性评估：一项病例对照研究。
Int J Epidemiol. 1995 Oct;24(5):1050-7. doi: 10.1093/ije/24.5.1050.
9
[Preventive effectiveness of an urgent mass vaccination with purified meningococcal polysaccharide vaccine observed during a meningitis epidemic].[在一次脑膜炎流行期间观察到的纯化脑膜炎球菌多糖疫苗紧急大规模接种的预防效果]
Zhonghua Liu Xing Bing Xue Za Zhi. 1985 Dec;6(6):344-6.
10
Current status of meningococcal group B vaccine candidates: capsular or noncapsular?B群脑膜炎球菌疫苗候选产品的现状：荚膜型还是非荚膜型？
Clin Microbiol Rev. 1994 Oct;7(4):559-75. doi: 10.1128/CMR.7.4.559.
引用本文的文献
1
Population coverage analysis of T-Cell epitopes of Neisseria meningitidis serogroup B from Iron acquisition proteins for vaccine design.用于疫苗设计的脑膜炎奈瑟菌B群铁摄取蛋白T细胞表位的人群覆盖率分析
Bioinformation. 2011;6(7):255-61. doi: 10.6026/97320630006255. Epub 2011 Jun 23.
2
Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes.脑膜炎奈瑟菌代谢建模：从基因组到代谢通量
Genome Biol. 2007;8(7):R136. doi: 10.1186/gb-2007-8-7-r136.
3
T-cell-stimulating protein A elicits immune responses during meningococcal carriage and human disease.T细胞刺激蛋白A在脑膜炎球菌携带和人类疾病期间引发免疫反应。
Infect Immun. 2005 Aug;73(8):4684-93. doi: 10.1128/IAI.73.8.4684-4693.2005.
4
Evidence of positive Darwinian selection in putative meningococcal vaccine antigens.假定的脑膜炎球菌疫苗抗原中存在正向达尔文选择的证据。
J Mol Evol. 2005 Jul;61(1):90-8. doi: 10.1007/s00239-004-0290-6. Epub 2005 Jun 29.
5
Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis.控制流行性脑膜炎球菌性脑膜炎免疫策略的成本效益综述
Pharmacoeconomics. 2005;23(4):333-43. doi: 10.2165/00019053-200523040-00004.
6
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870.使用脂蛋白GNA1870的三种变体对脑膜炎奈瑟菌进行疫苗接种。
J Exp Med. 2003 Mar 17;197(6):789-99. doi: 10.1084/jem.20021911.
7
NadA, a novel vaccine candidate of Neisseria meningitidis.NadA，一种新型的脑膜炎奈瑟菌疫苗候选物。
J Exp Med. 2002 Jun 3;195(11):1445-54. doi: 10.1084/jem.20020407.
8
Neisserial immunoglobulin A1 protease induces specific T-cell responses in humans.奈瑟菌免疫球蛋白A1蛋白酶可诱导人类产生特异性T细胞反应。
Infect Immun. 2002 Jan;70(1):335-44. doi: 10.1128/IAI.70.1.335-344.2002.
9
Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development.1997 - 1998年期间在巴西分离出的B群脑膜炎奈瑟菌的血清亚型和PorA类型：概述及其对疫苗研发的意义。
J Clin Microbiol. 2001 Aug;39(8):2897-903. doi: 10.1128/JCM.39.8.2897-2903.2001.
10
Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine.古巴抗脑膜炎球菌BC疫苗诱导的免疫反应及可能参与其提供保护作用的新效应机制。
Infect Immun. 2001 Jul;69(7):4502-8. doi: 10.1128/IAI.69.7.4502-4508.2001.
本文引用的文献
1
Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.A、B和C群脑膜炎球菌多糖-破伤风类毒素结合物的免疫化学
J Immunol. 1981 Sep;127(3):1011-8.
2
Five structural classes of major outer membrane proteins in Neisseria meningitidis.脑膜炎奈瑟菌主要外膜蛋白的五种结构类型。
J Bacteriol. 1981 Apr;146(1):69-78. doi: 10.1128/jb.146.1.69-78.1981.
3
Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children.对A群脑膜炎奈瑟菌荚膜多糖疫苗的血清抗体在婴幼儿和儿童中进行了三年的随访。
J Infect Dis. 1980 Dec;142(6):861-8. doi: 10.1093/infdis/142.6.861.
4
Physicochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods.两种方法制备的A群脑膜炎球菌多糖-破伤风类毒素结合物的物理化学及免疫学特性
Vaccine. 1983 Dec;1(1):31-6. doi: 10.1016/0264-410x(83)90010-5.
5
6
Use of a zwitterionic detergent for the restoration of the antibody-binding capacity of electroblotted meningococcal outer membrane proteins.使用两性离子去污剂恢复电印迹脑膜炎球菌外膜蛋白的抗体结合能力。
J Immunol Methods. 1984 Feb 24;67(1):1-11. doi: 10.1016/0022-1759(84)90080-2.
7
Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines.C群脑膜炎球菌多糖-破伤风类毒素结合物作为新一代疫苗的制备及免疫化学特性分析
Infect Immun. 1983 Apr;40(1):39-45. doi: 10.1128/iai.40.1.39-45.1983.
8
Prevention of meningococcal disease by group C polysaccharide vaccine.C群多糖疫苗预防脑膜炎球菌病
N Engl J Med. 1970 Feb 19;282(8):417-20. doi: 10.1056/NEJM197002192820803.
9
Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.人类对脑膜炎球菌的免疫力。IV. A群和C群脑膜炎球菌多糖对人类志愿者的免疫原性。
J Exp Med. 1969 Jun 1;129(6):1367-84. doi: 10.1084/jem.129.6.1367.
10
Quantitative determination of the human immune response to immunization with meningococcal vaccines.对脑膜炎球菌疫苗免疫接种的人体免疫反应的定量测定。
J Clin Invest. 1972 Jan;51(1):89-96. doi: 10.1172/JCI106801.
Zotero 插件